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ABSTRACT
Background/Aims: Genetic variants of MHC class I polypeptide-related chain A 
(MICA) at rs2596542 have been associated with hepatocellular carcinoma. The linkage 
between serum MICA (sMICA) and liver fibrosis in chronic hepatitis C is elusive.
Results: Linear regression analysis revealed that sMICA were independently 
correlated to α-fetoprotein (β: 0.149; 95% confidence interval [CI]: 0.001, 0.003; 
P = 0.007)and MICA rs2596542 GG genotype (β: 0.209; 95% CI: 0.153, 0.483; 
P < 0.001). While patients were stratified by MICA genetic variants, advanced fibrosis 
was the only factor independently correlated to sMICA among A allele carriers (β: 
0.234; 95% CI: 0.107, 0.543; P = 0.004) but not among non-A allele carriers. Logistic 
regression analysis revealed that factors associated with advanced liver fibrosis 
was sMICA (OR/CI: 2.996/1.428–6.287, P = 0.004) and platelet counts (OR/CI: 
0.988/0.982–0.994, P < 0.001) in MICA rs2596542 A allele carriers. sMICA > 50 pg/mL  
provided a positive predictive value of 72 % in predicting advanced liver fibrosis (F3-4) 
and of 90% in significant fibrosis (> F2) in MICA rs2596542 A allele carriers.
Materials and Methods: Serum level and single nucleotide polymorphism at 
rs2596542 of MICA were tested for the association with liver fibrosis in 319 biopsy 
proven chronic hepatitis C patients.
Conclusions: Levels of sMICA were highly correlated to liver disease severity 
in chronic hepatitis C patients who carried the MICA rs738409 A allele. Patients 
possessing the genetic predisposition had a higher likelihood of progressed liver 
fibrosis if they expressed higher sMICA levels.
INTRODUCTION
Chronic hepatitis C (CHC) infection is one of 
the leading causes of end sage liver diseases including 
hepatocellular carcinoma (HCC) [1]. Fibrogenesis is a 
critical pathophysiological element for clinical deterioration 
in CHC patients. The rate of liver fibrosis progression 
varies and the major determinants include viral factors 
(ex. hepatitis B virus [HBV] and human immunodeficiency 
virus [HIV] co-infection), environmental factors 
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(ex. alcohol) and host factors (ex. diabetic mellitus, age, 
age of infection, steatosis and host genetics [2–5]). 
When it comes to host genetics, a genome-wide 
association study (GWAS) has confirmed that the single 
nucleotide polymorphism (SNP) rs2596542 of MHC class 
I polypeptide-related chain A (MICA) was significantly 
associated with hepatitis C virus (HCV) related HCC [6]. 
MICA is the ligand for natural killer group 2D (NKG2D). 
It activates natural killer cells and CD8+ T cells, which 
in turn express anti-tumor effects. However, high 
expression soluble MICA (sMICA) in the circulation 
might down-regulate NKG2D expression. It may further 
disturb NKG2D-mediated antitumor immunity. We have 
demonstrated the impact of the SNP and its serum levels 
on HCC occurrence upon a HCV post-treatment cohort 
[7]. In view of liver disease severity, it has been suggested 
that HCV-related liver cirrhosis has higher sMICA levels 
compared to uninfected subjects [8]. However, whether the 
sMICA could serve as a biomarker of liver fibrosis among 
CHC patients has never been explored. Furthermore, the 
expression of sMICA varies between subjects who carry 
different MICA rs2596542 genotypes [6, 8]. It is imperative 
to explore the issue by judging patients with different 
genetic backgrounds. In the current study, we aimed to 
elucidate the association of sMICA with HCV-related liver 
fibrosis in patients with different genetic predispositions.
RESULTS
Patient characteristics 
The basic demographical, virological, and clinical 
features of the 319 patients are shown in Table 1. The 
mean patient age was 52.9 ± 11.3 years. Males accounted 
for the 51.7% of the population. The mean HCV RNA 
levels were 5.55 ± 0.96 log IU/ml and 65.8% of the 
patients were infected with HCV genotype 1. Patients 
with advanced fibrosis (F3-4) accounted for 49.2% of 
the population. The mean sMICA level was 1.50 ± 0.76 
log pg/mL, and the proportion of patients with MICA 
rs2596542 A allele carriage was 49.2 % (n = 157). The 
MICA rs2596542 SNP distribution and sMICA level did 
not differ between patients with or with advanced liver 
disease among the entire population.
Association of sMICA with liver fibrosis in 
patients with different MICA rs2596542 
genotypes
Linear regression analysis revealed that factors 
independently correlated to sMICA were α-fetoprotein 
(β: 0.149; 95% confidence interval [CI]:0.001, 0.003; 
P =  0.007) and the MICA rs2596542 GG genotype 
(β: 0.209; 95% CI: 0.153, 0.483; P < 0.001). The MICA 
SNP was the strongest factor correlated with sMICA levels, 
and we further explored the factors correlated with sMICA 
in patients with different MICA SNPs. α-fetoprotein was 
independently correlated to sMICA in MICA rs2096542 
non-A allele carriers ((β: 0.158; 95 % CI: 0.000, 0.003; 
P =  0.049). On the other hand, advanced fibrosis (F34) 
was the only factor independently correlated to sMICA 
among MICA A allele carriers (β: 0.234; 95% CI: 0.107, 
0.543; P = 0.004) (Table 2). There was a significantly 
increased trend of sMICA levels from mild to severe 
fibrotic stages among the A allele carriers (P = 0.0009) but 
not the non-A allele (P = 0.79) carriers (Figure 1).
Levels of sMICA in predicting liver fibrosis in 
MICA rs2596542 A allele carriers
Serum MICA levels correlated with liver disease 
severity only in MICA rs2596542 A allele carriers. We 
further evaluate different cut-off values of sMICA in 
predicting liver fibrosis in the subpopulation. As shown 
in Tble 3, detectable sMICA (> 5.18 pg/mL) or sMICA 
> 50 pg/mL could differentiate patients with different 
degrees of liver fibrosis. sMICA > 50 pg/mL provided a 
positive predictive value of 72% in predicting advanced 
liver fibrosis (F34) and of 90% in significant fibrosis 
(> F2). The different cut-off values of APRI and FIB4 in 
predicting liver fibrosis defined by WHO [9] were also 
compared in Table 3. 
Factors associated with advanced liver disease 
in patients with or without MICA rs2596542 A 
allele carriage
A univariate analysis of factors associated with 
advanced liver fibrosis in the entire population included 
an older age, a lower platelet count, and higher aspartate 
aminotransferase, r-glutamyl transferase, and α-fetoprotein 
levels (Table 1). A logistic regression analysis of the 
factors that were associated with advanced liver fibrosis 
included platelet counts (OR/CI:0.987/0.982–0.991, 
P < 0.001) and r-GT (1.005/1.000–1.009, P = 0.04). The 
result was similar to that of the patients with MICA non-A 
allele carriage, of whom factors independently associated 
with advanced liver fibrosis were platelet counts (OR/
CI:0.986/0.979–0.993, P < 0.001) and r-GT (1.011/1.003-
1.019, P = 0.009) (Table 4 and Table 5). On the other hand, 
a univariate analysis of factors associated with advanced 
liver fibrosis among MICA A allele carriers included an 
older age, lower platelet counts, and higher AST, AFP and 
sMICA levels (Table 4). A logistic regression analysis of 
the factors associated with advanced liver fibrosis included 
sMICA (OR/CI:2.996/1.428–6.287, P = 0.004) and platelet 
counts (OR/CI:0.988/0.982–0.994, P < 0.001) (Table 5).
DISCUSSION
Until now, studies regarding the association of 
MICA SNP and its serum levels with liver disease 
Oncotarget32620www.impactjournals.com/oncotarget
mainly focus on HCC [6–8, 10]. The correlation with 
HCV related liver fibrosis has never been discussed. We 
demonstrated that sMICA level was correlated to HCV 
related liver disease severity. However, the association 
was only restricted to MICA rs2596542 A allele carriers. 
There was an increasing trend of sMICA levels with 
the progression of liver fibrosis among A allele carriers. 
Furthermore, higher sMICA was independently associated 
with advanced liver fibrosis, and nine-tenths of the A allele 
carriers possessed significant liver fibrosis if their sMICA 
level was > 50 pg/mL.
The carriage of MICA rs2596542 A allele had low 
MICA production [6, 8]. The low affinity of NKG2D on 
natural killer (NK) cells is postulated to be the cause of 
HCC in CHC [8]. However, escaping immune surveillance 
may take place if soluble MICA in the circulation is 
overproduced, which might down-regulate NKG2D 
expression and disturb NKG2D-mediated antitumor 
immunity. As a consequence, the high levels of sMICA 
have been associated with a variety of malignancies, 
including melanoma, breast, colon, and HCC [11, 12]. 
However, evidence for the association of MICA SNP 
rs2596542 and sMICA with liver fibrosis is sparse. Kumar 
et al. have observed a higher sMICA level in cirrhotic 
CHC patients compared to uninfected healthy controls. 
However, they did not identify any differences between 
CHC patients with or without liver cirrhosis [8]. In line 
with previous reports [6, 8], the carriage of the rs2596542 
Table 1: Basic characteristics of the patients
All patients
(n = 319)
F0-2
(n = 162)
F3-4
(n = 157) P value
Age (years, mean ± SD) 52.9 ± 11.3 51.0 ± 11.9 54.8 ± 10.2 0.003
Male gender, n (%) 165 (51.7) 85 (52.5) 80 (51.0) 0.79
Body weight (kg, mean ± SD) 66.8 ± 11.8 65.8 ± 11.5 67.9 ± 12.1 0.11
DM, n (%) 56 (17.6) 23 (14.2) 33 (21.0) 0.11
Platelet count (× 103 u/L, mean ± SD) 160 ± 64 184 ± 62 136 ± 57 < 0.001
r-GT (U/L,mean ± SD) 68.8 ± 57.8 58 ± 52 80 ± 61 0.001
AST (IU/L, mean ± SD) 104 ± 59 96 ± 54 112 ± 64 0.02
ALT (IU/L, mean ± SD) 150 ± 97 151 ± 96 149 ± 97 0.84
α-fetoprotein (ng/mL, mean ± SD) 21.2 ± 59.8 11.2 ± 15.0 31.4 ± 82.7 0.003
HCV genotype 1, n (%) 210 (65.8) 111 (68.5) 99 (63.1) 0.30
HCV RNA (log IU/mL, mean ± SD) 5.55 ± 0.96 5.63 ± 0.99 5.46 ± 0.93 0.11
MICA rs2596542 A allele, n (%) 157 (49.2) 73 (45.1) 84 (53.5) 0.13
sMICA (log pg/mL,mean ± SD) 1.50 ± 0.76 1.44 ± 0.76 1.57 ± 0.76 0.10
Note: HCV, hepatitis C virus;MICA: MHC class Ipolypeptide-related chain A;sMICA: serum MICA level; r-GT: r-glutamyl 
transferase; SD: standard deviation; DM: diabetes mellitus; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
Table 2: Linear regression analysis of factors associated with serum MICA level
B Standard error  95% confidence intervals for B Beta P value
All patients
α-fetoprotein 0.002 0.001 0.001 0.003 0.149 0.007
MICA rs2596542 GG genotype 0.318 0.084 0.153 0.483 0.209 < 0.001
MICA non-A allele carriers
α-fetoprotein 0.002 0.001 .000 0.003 0.158 0.049
MICA A allele carriers
F34 0.325 0.11 0.107 0.543 0.234 0.004
Note: Variables including age, sex, body weight, HCV genotype (1 vs. non-1), HCV viral loads, diabetes (yes vs. no), fibrosis 
(F0-2 vs. F34), platelet, α-fetoprotein,aspartate aminotransferase, alanine aminotransferase, r-glutamyl transferase.MHC class 
Ipolypeptide-related chain Ars2596542 GG genotype(A vs. non-A allele carriage). Odds ratio are for MICArs2596542 GG 
genotype(A vs. non-A allele carriage), α-fetoprotein (per 1 ng/mL increase), and fibrosis (F34 vs. F0-2).
Oncotarget32621www.impactjournals.com/oncotarget
Table 3: Predictive values of sMICA in predicting liver fibrosis for MICArs2596542 A allele 
carriers
Non-advanced fibrosis
F0-2 (N = 73)
n (%)
Advanced fibrosis
F34 (N = 84)
n (%) P value
SEN SPE PPV NPV
% % % %
sMICA detectable 27 (37.0) 53 (63.1) < 0.001 63 63 66 60
sMICA > 50 pg/mL 16 (21.9) 41 (48.8) < 0.001 49 78 72 57
sMICA > 100 pg/mL 11 (15.1) 23 (27.4) 0.06 27 85 68 50
Non-significant fibrosis
 F01 (N = 45)
n (%)
Significant fibrosis
F2-4 (N = 112)
n (%) P value
SEN SPE PPV NPV
% % % %
sMICA detectable 16 (35.6) 64 (57.1) 0.01 57 64 80 38
sMICA > 50 pg/mL 6 (13.3) 51 (45.5) < 0.001 46 87 90 39
sMICA > 100 pg/mL 5 (11.1) 29 (25.9) 0.04 26 89 85 33
FIB4 > 3.25* 9 (20.0) 65 (58.0) < 0.001 58 80 88 43
APRI > 1.5* 14 (31.1) 70 (62.5) < 0.001 63 69 83 43
Non cirrhosis
 F0-3 (N = 95)
n (%)
Cirrhosis
F4 (N = 62)
n (%) P value
SEN SPE PPV NPV
       % % % %
sMICA detectable 42 (44.2) 38 (61.3) 0.04 61 56 48 69
sMICA > 50 pg/mL 28 (29.5) 29 (46.8) 0.03 47 71 51 67
sMICA > 100 pg/mL 17 (17.9) 17 (27.4) 0.16 27 82 50 63
APRI > 2* 34 (35.8) 32 (51.6) 0.05 52 64 49 67
Note:MICA:MHC class Ipolypeptide-related chain A.Detectable sMICA: > 5.18 pg/mL. APRI: the aspartate aminotransferase-
to-platelet ratio index.FIB-4:fibrosis index based on four factors.* Cut-off values of FIB4 and APRI defined by WHO. 
Figure 1: Serum MICA levels in patients with different fibrotic stages stratified by MICA rs2596542 single nucleotide 
polymorphism. MICA, MHC class I polypeptide-related chain A.
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Table 4: Univariate analysis of factors associated with advanced liver fibrosis in patients with 
different MICA rs2596542 SNP
MICA rs2596542 
non-A allele carriers
MICA rs2596542
A allele carriers
F0-2
(n = 89)
F3-4
(n = 73) P value
F0-2
(n = 73)
F3-4
(n = 84) P value
Age (years, mean ± SD) 51.4 ± 11.9 55.2 ± 8.5 0.02 50.6 ± 12.0 54.3 ± 11.6 0.049
Male gender, n (%) 45 (50.6) 35 (47.9) 0.74 40 (54.8) 45 (53.6) 0.88
Body weight (kg, mean ± SD) 65.2 ± 12.4 68.2 ± 11.9 0.13 66.5 ± 10.3 67.7 ± 12.3 0.51
Diabetes, n (%) 13 (14.6) 16 (21.9) 0.11 10 (13.7) 17 (20.2) 0.28
Platelet count (× 103 u/L, mean ± SD) 183 ± 59 136 ± 58 < 0.001 184 ± 65 137 ± 57 < 0.001
AST (IU/L, mean ± SD ) 91 ± 51 107 ± 54 0.047 102 ± 57 116 ± 71 0.18
ALT (IU/L, mean ± SD) 141 ± 92 143 ± 68 0.92 163 ± 101 154 ± 117 0.62
r-GT (U/L,mean ± SD) 51 ± 36 86 ± 73 < 0.001 67 ± 66 74 ± 49 0.45
α-fetoprotein (ng/ml, mean ± SD) 9.9 ± 13.2 40.2 ± 115.2 0.02 12.8 ± 16.8 24.0 ± 36.1 0.02
HCV genotype 1, n (%) 63 (70.3) 43 (58.9) 0.11 48 (65.8) 56 (66.7) 0.9
HCV viral loads (log IU/mL, mean ± SD) 5.71 ± 0.97 5.56 ± 0.91 0.29 5.54 ± 1.00 5.38 ± 0.94 0.33
MICA rs2596542 A allele, n (%) - - - - - -
sMICA (log pg/mL. mean ± SD ) 1.67 ± 0.78 1.67 ± 0.82 0.96 1.15 ± 0.63 1.50 ± 0.70 0.001
sMICA > 50 pg/mL, n (%) 50 (56.2) 40 (54.8) 0.86 16 (21.9) 41 (48.8) <0.001
Note:HCV, hepatitis C virus;MICA: MHC class Ipolypeptide-related chain A;sMICA: serum MICA level; r-GT: r-glutamyl 
transferase; SD: standard deviation; DM: diabetes mellitus; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
Table 5: Logistic regression analysis of factors associated with advanced liver disease
Variables OR 95% C.I. P value
All patients
Platelet count
Per 1 u/Lincrease 0.987 0.982–0.991 < 0.001
r-GT
Per 1 U/L increase 1.005 1.000–1.009 0.04
MICA rs2596542 non-A allele carriers 
Platelet count
Per 1 u/L increase 0.986 0.979–0.993 < 0.001
r-GT
Per 1 U/L increase 1.011 1.003–1.019 0.009
MICA rs2596542 A allele carriers
Platelet count
Per 1 u/L increase 0.988 0.982–0.994 < 0.001
sMICA
< 50 pg/mL 1 0.004
> 50 pg/mL 2.996 1.428–6.287
Note:MICA: MHC class Ipolypeptide-related chain A.sMICA: serum MICA level; r-GT: r-glutamyl transferase.
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GG genotype was the strongest factor correlating with 
sMICA level. The association of sMICA with liver 
fibrosis should be discussed separately in patients who 
carry different MICA SNPs. In the current study, neither 
the MICA SNP nor sMICA were associated with advanced 
liver disease among the whole population. Nevertheless, 
sMICA levels were independently associated with 
fibrosis in A allele carriers. Unlike GG genotype carriers 
whose sMICA were secreted abundantly regardless 
liver disease severity, sMICA increased in proportion to 
the liver fibrotic stages in A allele carriers. The actual 
pathophysiological mechanism is unknown, whether 
the shedding protein of MICA contributes interactively 
to fibrogenesis (ex. A Disintegrin And Metalloprotease, 
ADAM [13]) awaits further exploration. 
In the current study, we demonstrated higher sMICA 
levels were independently associated with advanced liver 
disease in A allele carriers. A allele carriers with sMICA 
> 50 pg/mL had a three-fold risk of advanced liver 
fibrosis, including liver cirrhosis (F34), compared to their 
counterparts. The recommended treatment guidelines 
have proposed patients with F2 should be justified as a 
treatment priority [14, 15]. We concordantly proved 
a higher HCC risk in Taiwanese CHC patients with 
fibrotic stage 2 if they were left untreated [6].  WHO has 
advocated that CHC patients whose fibrotic stage is equal 
or greater than two have “significant fibrosis” [9].In the 
current study, we identified a 90 % PPV of significant 
fibrosis in A allele carriers whose sMICA > 50 pg/mL. 
APRI and FIB4 are now widely adapted as non-invasive 
markers for predicting liver fibrosis.9 The predictive power 
of sMICA was not inferior to and even substantially better 
than other two surrogates in terms of positive predictive 
value or specificity, which may provide insight for the 
individualized application on the basis of host genetics.
The current study was limited due to its cross 
sectional design. We failed to demonstrate the influence of 
the genetics in liver disease progression by a longitudinal 
observation. The application of biomarker is genetic-
dependent and may not be generalized to all patients. 
However, we have identified the clinical utility for 
predicting liver disease by measuring sMICA. The genetic 
test of MICA may facilitate the application of surrogate 
markers for HCC as well as liver fibrosis. In conclusion, 
serum MICA levels were highly correlated to liver disease 
severity in CHC patients who carried the MICA rs738409 
A allele. The current study might shed light for further 
fibrogenesis molecular experiments as well as potential 
antifibrotic agents development. Studies upon other 
ethnicities or etiologies of liver disease are warranted to 
validate the current finding. 
MATERIALS AND METHODS
Eligible patients were biopsy-proven CHC patients 
who planned to undergo antiviral therapy in a medical center 
in Taiwan. Patients were excluded if they were co-infected 
with HIV or hepatitis B virus (HBV) infection. Patients 
were also excluded if they had the following diseases: 
autoimmune hepatitis, primary biliary cirrhosis, a current 
or past history of alcohol abuse (≥ 20 g daily), previous 
liver transplantation, or a past history of HCC. Anti–
HCV antibodies were detected using a third-generation, 
commercially available enzyme-linked immunosorbent 
assay kit (AxSYM 3.0, Abbott Laboratories, Chicago, 
IL, USA). The biochemical items were measured on a 
multichannel auto analyzer (Hitachi Inc. Tokyo, Japan). 
Serum HCV RNA was detected using qualitative real-time 
polymerase chain reaction (PCR) (COBAS AMPLICOR 
Hepatitis C Virus Test, ver. 2.0; Roche, Branchburg, NJ, 
USA, detection limit: 50 IU/ml) or quantification branched 
DNA assay (Versant HCV RNA 3.0, Bayer, Tarrytown, New 
Jersey, USA; quantification limit: 615 IU/ml) if evaluated 
before 2011. The HCV genotypes were determined using 
the Okamoto method before 2011 [17]. After 2011, both 
the HCV RNA and genotype were detected using real-
time PCR assays (Real Time HCV; Abbott Molecular, Des 
Plaines, IL, USA; detection limit: 12 IU/ml) [18].The liver 
histology was graded and staged according to the scoring 
system described by Scheuer [19].Liver disease severity, 
including significant fibrosis (> F2)9, advanced liver fibrosis 
(F34)2, and cirrhosis (F4), was judged for its association 
with sMICA. The study was approved by the ethics 
committees at the participating hospitals and was performed 
according to the guidelines of the International Conference 
on Harmonization for Good Clinical Practice. All patients 
gave written informed consent before enrollment.
MICA rs2596542 genotyping and sMICA 
measurement
SNP rs2596542 of MICA was determined by ABI 
TaqMan® SNP genotyping assays (Applied Biosystems, 
Foster City, CA, USA) using pre-designed, commercial 
genotyping assays (ABI Assay ID: C__27301153_10). 
Briefly, PCR primers and two allelic-specific probes were 
designed to detect a specific SNP target. PCR reactions 
were performed in 96-well microplates with ABI 7500 
real-time PCR. Allele discrimination was achieved by 
detecting fluorescence using System SDS software 
version 1.2.3. The allele and genotype frequencies were 
consistent with Hardy-Weinberg equilibrium. sMICA was 
measured by a sandwich enzyme-linked immunosorbent 
assay (DuoSet MICA eELISA kits, R & D Systems, 
Minneapolis, MN, USA).
Statistical analyses 
The frequency was compared between groups using 
the χ2 test with the Yates correction or using Fisher’s exact 
test. Group means, presented as the mean values and standard 
deviations, were compared using analysis of variance and 
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Student’s t test or the Mann-Whitney U test. The serum HCV 
RNA levels were expressed after logarithmic transformation 
of the original values. The aspartate aminotransferase 
(AST)-to-platelet ratio index (APRI) was calculated by 
the following equation: (AST level/upper limit of normal 
range)/platelet counts (109/L) × 100. Fibrosis index based 
on four factors (FIB-4) was calculated as age ([yr] × AST 
[U/L])/((PLT [10(9)/L]) × (ALT [U/L])(1/2)). MICA SNP 
rs2596542 A allele carriage has been a risk factor of HCC in 
CHC [8]. The influence of the MICA SNP on liver fibrosis 
was calculated using a dominant (genotype GG vs. AG/AA) 
genetic model of inheritance. A stepwise logistic regression 
analysis was performed to evaluate the independent factors 
associated with advanced liver fibrosis by analyzing co-
variants with P values < 0.05 in the univariate analysis. The 
statistical analyses were performed using the SPSS 12.0 
statistical package (SPSS, Chicago, IL, USA). All statistical 
analyses were based on two-tailed hypothesis tests with a 
significance level of P < 0.05.
Abbreviations 
ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; APRI, the aspartate aminotransferase-
to-platelet ratio index; AFP, α-fetoprotein; CHC, chronic 
hepatitis C; GWAS, genome-wide association study; HCC, 
hepatocellular carcinoma; HCV, hepatitis C virus; MICA, 
MHC class I chain-related A; SNP, single-nucleotide 
polymorphism. 
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